ArticleIntestinal research2025

Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn's disease.

Robert Gilmore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.